You just read:

Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma

News provided by

Marker Therapeutics, Inc.

Jun 20, 2019, 07:00 ET